

# Jie Lu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10712065/publications.pdf>

Version: 2024-02-01

35  
papers

7,074  
citations

172386

29  
h-index

360920

35  
g-index

36  
all docs

36  
docs citations

36  
times ranked

10052  
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro delivery of calcium ions by nanogated mesoporous silica nanoparticles to induce cancer cellular apoptosis. <i>Molecular Systems Design and Engineering</i> , 2017, 2, 384-392.	1.7	12
2	Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. <i>Chemistry - A European Journal</i> , 2016, 22, 14806-14811.	1.7	81
3	Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. <i>Chemistry - A European Journal</i> , 2016, 22, 9607-9615.	1.7	46
4	Frontispiece: Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. <i>Chemistry - A European Journal</i> , 2016, 22, .	1.7	0
5	Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. <i>Journal of Controlled Release</i> , 2016, 229, 183-191.	4.8	149
6	Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0137595.	1.1	9
7	Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. <i>BMC Cancer</i> , 2015, 15, 381.	1.1	26
8	Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 95, 40-49.	6.6	228
9	Functional Nanovalves on Protein-Coated Nanoparticles for In vitro and In vivo Controlled Drug Delivery. <i>Small</i> , 2015, 11, 319-328.	5.2	65
10	Hybrid Mesoporous Silica Nanoparticles with pH-Operated and Complementary H-Bonding Caps as an Autonomous Drug-Delivery System. <i>Chemistry - A European Journal</i> , 2014, 20, 9372-9380.	1.7	40
11	Drug Release from Three-Dimensional Cubic Mesoporous Silica Nanoparticles Controlled by Nanoimpellers. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2014, 640, 588-594.	0.6	13
12	Two-Photon-Triggered Drug Delivery via Fluorescent Nanovalves. <i>Small</i> , 2014, 10, 1752-1755.	5.2	106
13	Two-Photon-Triggered Drug Delivery in Cancer Cells Using Nanoimpellers. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 13813-13817.	7.2	94
14	Involvement of Lysosomal Exocytosis in the Excretion of Mesoporous Silica Nanoparticles and Enhancement of the Drug Delivery Effect by Exocytosis Inhibition. <i>Small</i> , 2013, 9, 697-704.	5.2	137
15	Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association. <i>The Enzymes</i> , 2013, 34 Pt. B, 181-200.	0.7	12
16	Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy. <i>The Enzymes</i> , 2012, , 185-203.	0.7	3
17	In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 212-220.	1.7	192
18	Synthesis of Biomolecule-Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells. <i>Small</i> , 2011, 7, 1816-1826.	5.2	204

#	ARTICLE	IF	CITATIONS
19	Biocompatibility, Biodistribution, and Drug Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. <i>Small</i> , 2010, 6, 1794-1805.	5.2	947
20	Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian Cells. <i>Small</i> , 2010, 6, 1185-1190.	5.2	215
21	<i>In vivo</i> antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1218-1226.	1.9	72
22	Silica nanoparticles as a delivery system for nucleic acid-based reagents. <i>Journal of Materials Chemistry</i> , 2009, 19, 6308.	6.7	72
23	Light-Activated Nanoimpeller-Controlled Drug Release in Cancer Cells. <i>Small</i> , 2008, 4, 421-426.	5.2	430
24	Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery. <i>ACS Nano</i> , 2008, 2, 889-896.	7.3	1,758
25	Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs. <i>Small</i> , 2007, 3, 1341-1346.	5.2	927
26	Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. <i>Nanobiotechnology</i> , 2007, 3, 89-95.	1.2	175
27	Identification of Arctigenin as an Antitumor Agent Having the Ability to Eliminate the Tolerance of Cancer Cells to Nutrient Starvation. <i>Cancer Research</i> , 2006, 66, 1751-1757.	0.4	301
28	Angelmarin, a novel anti-cancer agent able to eliminate the tolerance of cancer cells to nutrient starvation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 581-583.	1.0	93
29	ARK5 Is a Tumor Invasion-Associated Factor Downstream of Akt Signaling. <i>Molecular and Cellular Biology</i> , 2004, 24, 3526-3535.	1.1	112
30	Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. <i>Cancer Science</i> , 2004, 95, 547-552.	1.7	103
31	Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. <i>Cancer Science</i> , 2004, 95, 685-690.	1.7	117
32	ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. <i>Oncogene</i> , 2003, 22, 6177-6182.	2.6	79
33	Identification of a Novel Protein Kinase Mediating Akt Survival Signaling to the ATM Protein. <i>Journal of Biological Chemistry</i> , 2003, 278, 48-53.	1.6	123
34	Kigamicins, Novel Antitumor Antibiotics: I. Taxonomy, Isolation, Physico-chemical Properties and Biological Activities. <i>Journal of Antibiotics</i> , 2003, 56, 1004-1011.	1.0	49
35	Kigamicins, Novel Antitumor Antibiotics: II. Structure Determination. <i>Journal of Antibiotics</i> , 2003, 56, 1012-1017.	1.0	40